Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the PROVAUR stewardship programme on linezolid resistance in a tertiary university hospital: a before-and-after interventional study.
García-Martínez L, Gracia-Ahulfinger I, Machuca I, Cantisán S, De La Fuente S, Natera C, Pérez-Nadales E, Vidal E, Rivero A, Rodríguez-Lopez F, Del Prado JR, Torre-Cisneros J. García-Martínez L, et al. Among authors: de la fuente s. J Antimicrob Chemother. 2016 Sep;71(9):2606-11. doi: 10.1093/jac/dkw179. Epub 2016 May 30. J Antimicrob Chemother. 2016. PMID: 27246230 Free article.
Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up.
Cárdenas MJ, de la Fuente S, Castro-Villegas MC, Romero-Gómez M, Ruiz-Vílchez D, Calvo-Gutiérrez J, Escudero-Contreras A, Del Prado JR, Collantes-Estévez E, Font P. Cárdenas MJ, et al. Among authors: de la fuente s. Rheumatol Int. 2017 Oct;37(10):1701-1708. doi: 10.1007/s00296-017-3757-7. Epub 2017 Jun 9. Rheumatol Int. 2017. PMID: 28597307
Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.
Cárdenas M, de la Fuente S, Castro-Villegas MC, Romero-Gómez M, Ruiz-Vílchez D, Calvo-Gutiérrez J, Escudero-Contreras A, Del Prado JR, Collantes-Estévez E, Font P. Cárdenas M, et al. Among authors: de la fuente s. Rheumatol Int. 2016 Dec;36(12):1627-1632. doi: 10.1007/s00296-016-3583-3. Epub 2016 Oct 24. Rheumatol Int. 2016. PMID: 27778067
Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
Cárdenas M, de la Fuente S, Font P, Castro-Villegas M, Romero-Gómez M, Ruiz-Vílchez D, Calvo-Gutiérez J, Escudero-Contreras A, Casado M, Del Prado J, Collantes-Estévez E. Cárdenas M, et al. Among authors: de la fuente s. Rheumatol Int. 2016 Feb;36(2):231-41. doi: 10.1007/s00296-015-3374-2. Rheumatol Int. 2016. PMID: 26494567
Corrigendum: Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos-Pinedo F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Among authors: de la fuente s. Front Immunol. 2024 Dec 19;15:1535051. doi: 10.3389/fimmu.2024.1535051. eCollection 2024. Front Immunol. 2024. PMID: 39749346 Free PMC article.
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Among authors: de la fuente s. Front Immunol. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676. eCollection 2024. Front Immunol. 2024. PMID: 39606235 Free PMC article.
Development of Biocompatible Digital Light Processing Resins for Additive Manufacturing Using Visible Light-Induced RAFT Polymerization.
Sarabia-Vallejos MA, De la Fuente SR, Tapia P, Cohn-Inostroza NA, Estrada M, Ortiz-Puerta D, Rodríguez-Hernández J, González-Henríquez CM. Sarabia-Vallejos MA, et al. Among authors: de la fuente sr. Polymers (Basel). 2024 Feb 8;16(4):472. doi: 10.3390/polym16040472. Polymers (Basel). 2024. PMID: 38399850 Free PMC article.
136 results